Melanie Sena

DSM Pharmaceuticals appoints a new business unit director of its DSM Biologics/BioSolutions businesses.

DSM Pharmaceutical Products opens a cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.

Novartis files Citizen Petition with FDA to maintain naming policy for all biologics to help ensure patient safety.

PhRMA reports 452 new medicines are in development for rare diseases, including genetic disorders, neurological conditions, infectious diseases, and autoimmune disorders.

Governor Jerry Brown cites physician notification requirements for dispensing biosimilars as premature in the absence of FDA specifications for interchangeability.

ABC Laboratories plans to move operations of its subsidiary, Morse Laboratories, based in California, to Missouri.

Soligenix has been awarded a multimillion BARDA contract for the advanced preclinical and manufacturing development of OrbeShield, a treatment for gastrointestinal acute radiation syndrome.

CHMP recommended 11 new medicines for approval, the most approval recommendations at a CHMP meeting thus far in 2013.

The CMDh agrees to suspend the marketing authorization of Numeta G13%E because of a risk of hypermagnesaemia.

CEO of Waters Corporation will retire within in the next two years.

Agilent Technologies opens multimillion dollar Spectroscopy Technology Innovation Center in Australia.

Sangamo BioSciences has agreed to acquire Ceregene, a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

AstraZeneca's MedImmune has agreed to acquire Amplimmune, which specializes in cancer immunology.

Amgen acquires Onyx Pharmaceuticals for $125 per share in cash.

Amgen, Servier collaborate ivabraline and other cardiovascular products.

New NIH policy requires researchers to apply for access to the full genome sequence data from HeLa cells.

iQur and the Edward Jenner Institute for Vaccine Research announced that that they will receive a grant of 152,000 EUR ($201,523) from the Technology Strategy Board's Biocatalyst fund to develop a novel malaria vaccine.

Designation granted by FDA for the treatment of trigeminal neuralgia.

Pfizer has announced plans to internally separate its commercial operations into three business segments.

A new method of vaccine design, called the Multiple Antigen Presentation System (MAPS), may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination.

Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement.

Wyeth Pharmaceuticals has agreed to pay $490.9 million to resolve its criminal and civil liability arising from the unlawful marketing of the prescription drug Rapamune for uses not approved as safe and effective by FDA.